BTK and B-cell chronic lymphocytic leukemia: This is in agreement with results from the Phase II CAPTIVATE study (NCT02910583), where CLL patients received frontline treatment with the targeted therapies venetoclax plus the BTK inhibitor ibrutinib [40].